Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETHECC: Thymitaq vs Doxorubicin in Unresectable Hepatocellular Carcinoma
NCT00012324Phase 3Completed
- Sponsor
- Eximias Pharmaceutical Corporation
- Start
- Sep 2000
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of nolatrexed in hepatocellular carcinoma (HCC) (2 arms), sponsored by Eximias Pharmaceutical Corporation. Primary endpoint: Overall Survival. Started Sep 2000; status: completed.
02
Drugs
nolatrexed
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00012324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00012324.